ArticleBMC pulmonary medicine2015
Circulating concentration of markers of angiogenic activity in patients with sarcoidosis and idiopathic pulmonary fibrosis.
Article in BMC pulmonary medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 28 citations in OpenAlex.
- Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis.The European respiratory journal · 2021Trial
- Serum VEGF Potential as a Biomarker for Diagnosis of Female Unexplained Infertility: Does Atopy Matter?International journal of molecular sciences · 2025Observational
- Cytokine Expression Profiling in Idiopathic Pulmonary Fibrosis: Insights From Integrative Proteomic Analysis.Canadian respiratory journal · 2025Article
- Follistatin-respiratory connection predicting all-cause mortality among community-dwelling middle-to-old age individuals: Results from the I-Lan Longitudinal Study.The journal of nutrition, health & aging · 2024Article
- Lymphocyte Subsets and Pulmonary Nodules to Predict the Progression of Sarcoidosis.Biomedicines · 2023Article
- Integrative single-cell analysis of cardiac and pulmonary sarcoidosis using publicly available cardiac and bronchoalveolar lavage fluid sequencing datasets.Frontiers in cardiovascular medicine · 2023Review
- Correlation between platelet-derived growth factor-B gene polymorphism and coronary heart disease.Journal of clinical laboratory analysis · 2022Article
- Pulmonary disease as a risk factor for transfusion-related acute lung injury.ERJ open research · 2021Article
- CD31Journal of thoracic disease · 2021Article
- Evaluation of [Frontiers in medicine · 2021Article
- Association of proangiogenic and profibrotic serum markers with lung function and quality of life in sarcoidosis.PloS one · 2021Article
- Exhaled Biomarkers in Idiopathic Pulmonary Fibrosis-A Six-Month Follow-Up Study in Patients Treated with Pirfenidone.Journal of clinical medicine · 2020Article
- Treprostinil inhibits proliferation and extracellular matrix deposition by fibroblasts through cAMP activation.Scientific reports · 2018Article
- An Adaptogen: Withaferin A AmelioratesFrontiers in pharmacology · 2018Article
- IL-8 mediates idiopathic pulmonary fibrosis mesenchymal progenitor cell fibrogenicity.American journal of physiology. Lung cellular and molecular physiology · 2018Article
- Mesenchymal stem cells in idiopathic pulmonary fibrosis.Oncotarget · 2017Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAngiogenesis is an important process involved in the pathogenesis of diffuse parenchymal lung diseases. The aim of the study was to compare the angiogenic profile of patients with sarcoidosis and idiopathic pulmonary fibrosis (IPF) based on analysis of circulating factors.
methodsSerum concentrations of angiopoietin-2 (Ang-2), follistatin, granulocyte-macrophage-colony stimulating factor (GM-CSF), interleukin-8 (IL-8), platelet derived growth factor-BB (PDGF-BB), platelet endothelial cellular adhesion molecule-1 (PECAM-1) and vascular endothelial growth factors (VEGF) were measured in the patients and the healthy subjects.
resultsSerum concentrations of G-CSF, follistatin, PECAM-1 and IL-8 were significantly higher in the IPF patients in comparison with the control group and the sarcoid patients. PDGF-BB concentrations were also significantly higher in serum of IPF patients than in sarcoid patients, but not than in the controls. In contrast, Ang-2 and VEGF concentrations did not differ significantly between the three groups. In the sarcoid patients, irrespective of the disease activity or the radiological stage, serum concentrations of these cytokines were similar to the control group.
conclusionsThese results indicate that differences may exist in angiogenic activity between patients with parenchymal lung diseases. In contrast to sarcoidosis, IPF is characterized by a higher serum concentration of different molecules involved in the angiogenic processes .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.